FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like Cellectar Biosciences Further Deepens Intellectual Property Portfolio With Patent Grant For PET Imaging PDC March 20, 2017 Prolacta Bioscience To Present At The 2017 Conference On February 22, 2017 February 21, 2017 This Little-Known $12 Billion SoCal Startup Wants to Cure Baldness and Smooth Out Your Wrinkles April 2, 2017
Cellectar Biosciences Further Deepens Intellectual Property Portfolio With Patent Grant For PET Imaging PDC March 20, 2017
This Little-Known $12 Billion SoCal Startup Wants to Cure Baldness and Smooth Out Your Wrinkles April 2, 2017
